Emily Grist

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2026

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2026

The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test.

The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 04, 2025

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Journal: Molecular cancer research : MCR

Published: November 28, 2025

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Journal: The Lancet. Oncology

Published: March 13, 2025

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 27, 2025

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Journal: Cell

Published: January 23, 2025

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

Journal: The Lancet. Digital health

Published: January 10, 2024

The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer.

The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: May 18, 2023

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Journal: Research square

Published: February 17, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026